<DOC>
	<DOC>NCT01550653</DOC>
	<brief_summary>This study examines the hypothesis, that subcutaneous administration of liraglutide, an analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in healthy humans.</brief_summary>
	<brief_title>Liraglutide Effects on Memory in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male sex Age 1835 years Body mass index between 19 and 25 kg/m2 Nonsmoker Receipt of any drug within 4 weeks prior to this trial Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas or gastrointestinal tract, any metabolic, endocrine or psychiatric disease. Brady and Tachycardia, i.e. heart rate &lt; 50 and &gt; 90 beats per minute. Hypertension (systolic blood pressure &gt; 150 mmHg, diastolic blood pressure &gt; 90 mmHg). Hyperlipidemia (cholesterol, LDL, triglyceride &gt; two times the upper reference limit based on analysis from the central laboratory) Impaired hepatic function measured as alanine aminotransferase (ALAT) &gt; two times the upper reference limit based on analysis from the central laboratory Impaired renal function measured as creatinine &gt; 120 Âµmol/l based on analysis from the central laboratory Family history of diabetes History of any eating disorder Known or suspected allergy to trial products History of drug or alcohol abuse within the last five years prior to screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Memory</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>energy output</keyword>
	<keyword>Memory facilitation</keyword>
	<keyword>GLP-1 analogue</keyword>
</DOC>